CN109072273B - 使用全乙酰基半乳糖调节重组蛋白的蛋白质半乳糖基化概况的方法 - Google Patents

使用全乙酰基半乳糖调节重组蛋白的蛋白质半乳糖基化概况的方法 Download PDF

Info

Publication number
CN109072273B
CN109072273B CN201780028831.1A CN201780028831A CN109072273B CN 109072273 B CN109072273 B CN 109072273B CN 201780028831 A CN201780028831 A CN 201780028831A CN 109072273 B CN109072273 B CN 109072273B
Authority
CN
China
Prior art keywords
peracetylgalactose
protein
cell
galactosylation
galactose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780028831.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN109072273A (zh
Inventor
M·乔丹
G·勒克莱尔
J·索奎特
H·布罗利
D·布鲁尔曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ares Trading SA
Original Assignee
Ares Trading SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading SA filed Critical Ares Trading SA
Publication of CN109072273A publication Critical patent/CN109072273A/zh
Application granted granted Critical
Publication of CN109072273B publication Critical patent/CN109072273B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/34—Sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN201780028831.1A 2016-05-10 2017-05-10 使用全乙酰基半乳糖调节重组蛋白的蛋白质半乳糖基化概况的方法 Active CN109072273B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16169062 2016-05-10
EP16169062.3 2016-05-10
PCT/EP2017/061181 WO2017194605A1 (en) 2016-05-10 2017-05-10 Methods for modulating protein galactosylation profiles of recombinant proteins using peracetyl galactose

Publications (2)

Publication Number Publication Date
CN109072273A CN109072273A (zh) 2018-12-21
CN109072273B true CN109072273B (zh) 2022-04-15

Family

ID=56026651

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780028831.1A Active CN109072273B (zh) 2016-05-10 2017-05-10 使用全乙酰基半乳糖调节重组蛋白的蛋白质半乳糖基化概况的方法

Country Status (9)

Country Link
US (1) US11118208B2 (enExample)
EP (1) EP3455363B1 (enExample)
JP (1) JP6882339B2 (enExample)
CN (1) CN109072273B (enExample)
AU (2) AU2017264541A1 (enExample)
CA (1) CA3022769A1 (enExample)
ES (1) ES2908067T3 (enExample)
IL (1) IL262875B (enExample)
WO (1) WO2017194605A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017117218A1 (en) 2015-12-30 2017-07-06 Momenta Pharmaceuticals, Inc. Methods related to biologics
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
MX2021008030A (es) * 2018-12-31 2021-08-05 Momenta Pharmaceuticals Inc Metodos para producir ustekinumab.
CN113549667A (zh) * 2021-07-21 2021-10-26 杭州奕安济世生物药业有限公司 一种降低抗体半乳糖基化的方法
WO2023161885A1 (en) * 2022-02-25 2023-08-31 Kashiv Biosciences, Llc A process for improving polypeptide expression in mammalian cell culture

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102076865A (zh) * 2008-05-02 2011-05-25 西雅图基因公司 用于制造核心岩藻糖基化降低的抗体和抗体衍生物的方法和组合物
CN103402525A (zh) * 2010-08-05 2013-11-20 西雅图基因公司 使用岩藻糖类似物在体内抑制蛋白质岩藻糖基化的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2943667C (en) * 2014-01-29 2022-11-08 Lg Life Sciences Ltd. Method for modulating galactosylation of recombinant protein through optimization of culture medium
WO2016022377A2 (en) * 2014-08-05 2016-02-11 Abbvie Inc. Methods for modulating the glycosylation profile of recombinant proteins using dissolved oxygen

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102076865A (zh) * 2008-05-02 2011-05-25 西雅图基因公司 用于制造核心岩藻糖基化降低的抗体和抗体衍生物的方法和组合物
CN103402525A (zh) * 2010-08-05 2013-11-20 西雅图基因公司 使用岩藻糖类似物在体内抑制蛋白质岩藻糖基化的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Control of Recombinant Monoclonal Antibody Effector Functions by Fc N‐Glycan Remodeling in Vitro;Jason Hodoniczky;《biotechnol.prog.》;20051007;第1644-1652页 *

Also Published As

Publication number Publication date
US20190153497A1 (en) 2019-05-23
US11118208B2 (en) 2021-09-14
JP2019514411A (ja) 2019-06-06
IL262875B (en) 2022-05-01
EP3455363A1 (en) 2019-03-20
IL262875A (en) 2018-12-31
AU2021258023B2 (en) 2023-11-16
EP3455363B1 (en) 2021-12-08
CA3022769A1 (en) 2017-11-16
AU2021258023A1 (en) 2021-11-25
AU2017264541A1 (en) 2018-12-13
ES2908067T3 (es) 2022-04-27
WO2017194605A1 (en) 2017-11-16
JP6882339B2 (ja) 2021-06-02
CN109072273A (zh) 2018-12-21

Similar Documents

Publication Publication Date Title
JP7267284B2 (ja) ポリエーテルイオノフォアを使用するタンパク質マンノシル化プロファイルの調節方法
AU2021258023B2 (en) Methods for modulating protein galactosylation profiles of recombinant proteins using peracetyl galactose
JP6971221B2 (ja) 組換えタンパク質のガラクトース含有量を増加させる方法
AU2016354052B2 (en) Methods for modulating production profiles of recombinant proteins
EP3969564A1 (en) Method for reducing methionine oxidation in recombinant proteins
CN108350415A (zh) 调节灌注模式中重组蛋白生产概况的方法
EP3325610B1 (en) Methods for modulating production profiles of recombinant proteins
US20240425894A1 (en) Cell culture processes
WO2016162514A1 (en) Methods for modulating protein glycosylation profiles of recombinant proteins
WO2021066772A1 (en) Cell culture medium for reducing fucosylation and basic variants in the production of antibodies

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant